All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What are novel strategies to treat low-risk MDS?
What are novel strategies to treat low-risk MDS?
Platzbecker overviews the current status for luspatercept, used for patients with ring sideroblasts refractory to erythropoiesis-stimulating agents. He then discusses a phase III trial for the telomerase inhibitor imetelstat in transfusion-dependent patients with low-risk MDS that is relapsed/refractory to erythropoiesis-stimulating agents.
Luspatercept approved for transfusion-dependent anemia in patients with MDS
Luspatercept: first-in-class erythroid maturation agent approved by the FDA and EMA for MDS.
What are the new approaches for anemia treatment in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to Bedside, the MDS Hub spoke to Uwe...
Subscribe to get the best content related to MDS delivered to your inbox